vs

Side-by-side financial comparison of InvenTrust Properties Corp. (IVT) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $77.4M, roughly 2.0× InvenTrust Properties Corp.). InvenTrust Properties Corp. runs the higher net margin — 3.4% vs -5.5%, a 9.0% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 8.6%). InvenTrust Properties Corp. produced more free cash flow last quarter ($110.9M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 7.6%).

InvenTrust Properties Corp. is a real estate investment trust that invests in shopping malls. As of December 31, 2024, the company owned interests in 68 properties comprising 11.0 million square feet.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

IVT vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
2.0× larger
TARS
$151.7M
$77.4M
IVT
Growing faster (revenue YoY)
TARS
TARS
+119.8% gap
TARS
128.4%
8.6%
IVT
Higher net margin
IVT
IVT
9.0% more per $
IVT
3.4%
-5.5%
TARS
More free cash flow
IVT
IVT
$97.9M more FCF
IVT
$110.9M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
7.6%
IVT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IVT
IVT
TARS
TARS
Revenue
$77.4M
$151.7M
Net Profit
$2.7M
$-8.4M
Gross Margin
Operating Margin
-11.0%
-5.3%
Net Margin
3.4%
-5.5%
Revenue YoY
8.6%
128.4%
Net Profit YoY
-72.8%
63.8%
EPS (diluted)
$0.02
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVT
IVT
TARS
TARS
Q4 25
$77.4M
$151.7M
Q3 25
$74.5M
$118.7M
Q2 25
$73.6M
$102.7M
Q1 25
$73.8M
$78.3M
Q4 24
$71.2M
$66.4M
Q3 24
$68.5M
$48.1M
Q2 24
$67.4M
$40.8M
Q1 24
$66.8M
$27.6M
Net Profit
IVT
IVT
TARS
TARS
Q4 25
$2.7M
$-8.4M
Q3 25
$6.0M
$-12.6M
Q2 25
$95.9M
$-20.3M
Q1 25
$6.8M
$-25.1M
Q4 24
$9.8M
$-23.1M
Q3 24
$-539.0K
$-23.4M
Q2 24
$1.5M
$-33.3M
Q1 24
$2.9M
$-35.7M
Operating Margin
IVT
IVT
TARS
TARS
Q4 25
-11.0%
-5.3%
Q3 25
-9.8%
-12.2%
Q2 25
-21.6%
Q1 25
-10.5%
-33.5%
Q4 24
-3.6%
-36.8%
Q3 24
-18.7%
-52.3%
Q2 24
-13.6%
-81.6%
Q1 24
-13.1%
-136.5%
Net Margin
IVT
IVT
TARS
TARS
Q4 25
3.4%
-5.5%
Q3 25
8.1%
-10.6%
Q2 25
130.4%
-19.8%
Q1 25
9.2%
-32.1%
Q4 24
13.8%
-34.8%
Q3 24
-0.8%
-48.7%
Q2 24
2.2%
-81.6%
Q1 24
4.3%
-129.4%
EPS (diluted)
IVT
IVT
TARS
TARS
Q4 25
$0.02
$-0.17
Q3 25
$0.08
$-0.30
Q2 25
$1.23
$-0.48
Q1 25
$0.09
$-0.64
Q4 24
$0.14
$-0.57
Q3 24
$-0.01
$-0.61
Q2 24
$0.02
$-0.88
Q1 24
$0.04
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVT
IVT
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$825.9M
$72.4M
Stockholders' EquityBook value
$1.8B
$343.4M
Total Assets
$2.8B
$562.2M
Debt / EquityLower = less leverage
0.46×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVT
IVT
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
IVT
IVT
TARS
TARS
Q4 25
$825.9M
$72.4M
Q3 25
$764.6M
$72.3M
Q2 25
$746.3M
$72.1M
Q1 25
$740.7M
$72.0M
Q4 24
$740.4M
$71.8M
Q3 24
$740.1M
$71.7M
Q2 24
$812.2M
$71.6M
Q1 24
$827.5M
$29.9M
Stockholders' Equity
IVT
IVT
TARS
TARS
Q4 25
$1.8B
$343.4M
Q3 25
$1.8B
$335.1M
Q2 25
$1.8B
$332.6M
Q1 25
$1.7B
$342.5M
Q4 24
$1.8B
$224.5M
Q3 24
$1.8B
$237.5M
Q2 24
$1.5B
$252.2M
Q1 24
$1.5B
$275.2M
Total Assets
IVT
IVT
TARS
TARS
Q4 25
$2.8B
$562.2M
Q3 25
$2.7B
$534.6M
Q2 25
$2.7B
$495.0M
Q1 25
$2.6B
$500.8M
Q4 24
$2.6B
$377.0M
Q3 24
$2.6B
$376.3M
Q2 24
$2.5B
$376.8M
Q1 24
$2.5B
$349.3M
Debt / Equity
IVT
IVT
TARS
TARS
Q4 25
0.46×
0.21×
Q3 25
0.42×
0.22×
Q2 25
0.41×
0.22×
Q1 25
0.42×
0.21×
Q4 24
0.42×
0.32×
Q3 24
0.42×
0.30×
Q2 24
0.53×
0.28×
Q1 24
0.53×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVT
IVT
TARS
TARS
Operating Cash FlowLast quarter
$155.4M
$19.3M
Free Cash FlowOCF − Capex
$110.9M
$13.0M
FCF MarginFCF / Revenue
143.3%
8.6%
Capex IntensityCapex / Revenue
57.5%
4.2%
Cash ConversionOCF / Net Profit
58.41×
TTM Free Cash FlowTrailing 4 quarters
$193.1M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVT
IVT
TARS
TARS
Q4 25
$155.4M
$19.3M
Q3 25
$43.8M
$18.3M
Q2 25
$48.7M
$-29.4M
Q1 25
$20.2M
$-20.7M
Q4 24
$136.9M
$-22.2M
Q3 24
$38.4M
$-8.7M
Q2 24
$46.7M
$-14.4M
Q1 24
$14.8M
$-37.8M
Free Cash Flow
IVT
IVT
TARS
TARS
Q4 25
$110.9M
$13.0M
Q3 25
$31.4M
$16.3M
Q2 25
$38.0M
$-30.4M
Q1 25
$12.8M
$-21.2M
Q4 24
$100.8M
$-22.3M
Q3 24
$29.3M
$-8.9M
Q2 24
$37.2M
$-15.4M
Q1 24
$7.7M
$-38.0M
FCF Margin
IVT
IVT
TARS
TARS
Q4 25
143.3%
8.6%
Q3 25
42.2%
13.8%
Q2 25
51.6%
-29.6%
Q1 25
17.4%
-27.1%
Q4 24
141.5%
-33.5%
Q3 24
42.8%
-18.6%
Q2 24
55.2%
-37.8%
Q1 24
11.5%
-137.5%
Capex Intensity
IVT
IVT
TARS
TARS
Q4 25
57.5%
4.2%
Q3 25
16.7%
1.6%
Q2 25
14.6%
1.0%
Q1 25
10.0%
0.8%
Q4 24
50.7%
0.1%
Q3 24
13.3%
0.6%
Q2 24
14.0%
2.5%
Q1 24
10.6%
0.6%
Cash Conversion
IVT
IVT
TARS
TARS
Q4 25
58.41×
Q3 25
7.27×
Q2 25
0.51×
Q1 25
2.97×
Q4 24
13.97×
Q3 24
Q2 24
31.15×
Q1 24
5.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons